News

Filter

Current filters:

Revia

1 to 9 of 52 results

Alkermes completes Ph IIIb Vivitrol enrollment

22-04-2009

US biotechnology firm Alkermes says that it has completed patient enrollment for the registration study…

Amino AcidsInjectionnaltrexoneNaltrexone XR InjPhysostigmine SalicylateReviaVivitrol

King's Embeda "effective for up to 12 months"

09-02-2009

The USA's King Pharmaceuticals says that results from a Phase III study show that Embeda (morphine sulfate…

AvinzaEmbedaKing PharmaceuticalsMorphine SulfateMorphine Sulfate and Naltrexone HydrochloridenaltrexoneReviaRoxanol

FDA review of King's Embeda likely to extend into "early 2009"

12-01-2009

King Pharmaceuticals says that the US Food and Drug Administration is continuing its review of the New…

EmbedaKing PharmaceuticalsMorphine Sulfate and Naltrexone HydrochloridenaltrexoneRevia

Alkermes regains the rights to Vivitrol from Cephalon along with $120M in revenue

08-12-2008

Alkermes has regained the full US rights to alcoholism treatment Vivitrol (naltrexone) from fellow US…

CephalonnaltrexoneNaltrexone XR InjReviaVivitrol

Syntropharma raises $2.4M in second round of investment

15-09-2008

Syntropharma, an early-stage Scottish drug developer focussed on transdermal patch delivery of reformulated…

naltrexoneReviaRisperdalRisperdal ConstaRisperidoneTestosteronetransdermal

1 to 9 of 52 results

COMPANY SPOTLIGHT

Menarini

Back to top